Introduction {#Sec1}
============

Multiple sclerosis (MS) is a heterogeneous disease of the central nervous system (CNS) characterized by immune cell infiltration, demyelination and neurodegeneration \[[@CR24]\]. The most common clinical form of MS is relapsing-remitting MS (RRMS), in which disease exacerbations are followed by periods of relative inactivity and recovery. The majority of RRMS patients eventually evolve into a progressive phase called secondary progressive MS (SPMS). In some patients, however, MS is progressive from the onset, referred to as primary progressive MS (PPMS). In both forms of progressive MS, clinical symptoms mostly reflect the underlying neurodegeneration. The pathological processes involved in the different phases of MS are relatively well defined. In RRMS, there is abundant immune cell invasion into the CNS through a dysfunctional and inflamed blood-brain barrier (BBB), leading to inflammatory white matter lesions. In progressive MS, neurodegeneration becomes more prominent and inflammation subsides, although lesion activity is still present \[[@CR21]\]. While immune cell infiltration through the BBB is reduced in progressive MS \[[@CR9], [@CR20]\], inflammatory processes at the other CNS barriers, such as those at the choroid plexus (CP) and meninges, may still contribute to the influx of peripheral immune cells. Indeed, it is known that chronic inflammation occurs in the meninges during progressive MS \[[@CR6], [@CR22], [@CR26]\], but less is known about the choroid plexus (CP) immune populations in progressive MS patients.

The CPs are secretory tissues strategically located within the CNS. They are the main producers of cerebrospinal fluid (CSF) and therefore essential for regulation of CNS homeostasis. The CPs are located in each of the brain ventricles and consist of highly vascularized stroma surrounded by a tight continuous layer of epithelial cells. The vasculature of the CPs is characteristically fenestrated, resulting in a leaky interphase between the blood and the CP stroma. The tight junctions that connect the epithelial cells restrict the entry of molecules and cells into the CSF. As such, the epithelial cell layer in the CP is a pivotal component of the blood-CSF barrier (BCSFB). The BCSFB allows for a tightly regulated bidirectional immunosurveillance system in which immune cells can traffic through the CP into the CNS, but also vice versa \[[@CR28]\]. Thus, the CPs, together with the BBB and the meninges, act as regulatory barriers for immune cells between the periphery and the CNS \[[@CR4], [@CR28]\].

Immune cells populate the CP under normal conditions, but a detailed overview of immune cell subsets that reside in the CP is currently lacking. The abundance of MHCII+ cells in the CP \[[@CR32]\] suggests that the CP may be involved in CSF monitoring and antigen presentation \[[@CR28]\]. Upon stimulation, immune cells located at the CP can secrete cytokines or infiltrate into the CNS \[[@CR17]\]. Accordingly, there is increasing evidence for the involvement of the CP immune component in MS. In the MS mouse model experimental autoimmune encephalomyelitis (EAE), the CP is an important early entry point for immune cells into the CNS \[[@CR23]\]. In MS patients, the CSF contains higher numbers of immune cells relative to the CSF in controls \[[@CR5], [@CR10]\], which also suggests an increased traversal of immune cells across the BCSFB. In progressive MS immune activation of the CP in a small cohort of SPMS patients has been reported previously \[[@CR32]\]. Together, studies suggest that the CP may act as a hub for the regulation of CNS immune homeostasis in MS pathology. On this basis, we here made a detailed assessment of human CP immune cell subsets and their localization within the CP compartments to better understand their role in MS pathogenesis.

We quantitatively and spatially characterized the CP immune cell distribution in progressive MS patients and non-neuroinflammatory controls. We show that granulocytes and T cells, particularly CD8+ T cells, are more abundant in the CP stroma of progressive MS patients compared to controls, but not in the CP epithelium. Moreover, we demonstrate that MHCII+ myeloid cells densely populate the CP of both progressive MS and control cases. Some of these cells appeared to be in close contact with T lymphocytes in the stroma regardless of the disease status, suggesting that antigen presentation is a constitutive process of the CP. Remarkably, B cells and plasma cells were virtually absent in the CP of both progressive MS and controls. Together, this paper highlights the importance of the CP in CNS immune homeostasis, and provides evidence for the involvement of T cells and granulocytes in the CP in the chronic progressive phases of MS.

Materials and Methods {#Sec2}
=====================

Human choroid plexus tissue {#Sec3}
---------------------------

Formalin fixed, paraffin embedded CP tissue from the lateral ventricles was obtained from patients with clinically diagnosed, neuro-pathologically confirmed progressive MS (*n* = 16) and non-neuroinflammatory control cases (*n* = 7) by rapid autopsy (Netherlands Brain Bank and Multiple Sclerosis Society Tissue Bank, funded by the Multiple Sclerosis Society of Great Britain and Northern Ireland, registered charity 207,495). All patients and controls, or their next of kin, had given informed consent for autopsy and use of their brain tissue for research purposes. Relevant clinical information was retrieved from the medical records and is summarized in Table [1](#Tab1){ref-type="table"}. Table 1Clinical data of MS patients and non-neuroinflammatory controlsSampleGenderAge at deathPMD (h)pH CSFBrain weight (g)DiagnosisCause of deathDisease duration (y)Brain BankControl1m5614:007.031323Non-demented controlTerminal congestive heart failurenaNBB2f787:106.321120Non-demented controlLegal euthanasianaNBB3f608:106.581310Non-demented controlMetastasized mammacarcinomanaNBB4f807:046.21450Non-demented controlLegal euthanasia with metastasisnaNBB5m937:406.21155Dementia with s.i.c.c.Heart failurenaNBB6m738:005.371553Non-demented controlInvasive fungal infection and bacterial pneumonianaNBB7f954:216.591169Non-demented controlIleus, palliative carenaNBBProgressive MS8m6610:557.28naMultiple sclerosis (PPMS)Legal euthanasia25NBB9m706:556.511230Multiple sclerosis (SPMS)Acute heart failure, *Clostridium difficile* colitis47NBB10f747:506.4975Multiple sclerosis (SPMS)Legal euthanasia50NBB11f609:2571295Multiple sclerosis (SPMS)Legal euthanasia with atrial fibrillations and fatigue22NBB12m547:556.61365Multiple sclerosis (SPMS)Legal euthanasia21NBB13f5710:406.761145Multiple sclerosis (SPMS)Legal euthanasia with ataxia25NBB14m828:056.71465Multiple sclerosis (PPMS)Pneumonia44NBB15m759:106.241140Multiple sclerosis (SPMS)nanaNBB16f837:406.541090Multiple sclerosis (PPMS)Ovarium carcinoma34NBB17f669:306.71243Multiple sclerosis (SPMS)Legal euthanasia25NBB18f4924:006.81006Multiple sclerosis (PPMS)Multiple sclerosisnaUK19f3915:00na998Multiple sclerosis (SPMS)Pulmonary embolism, pneumonia9UK20m5721:00na1280Multiple sclerosis (PPMS)Multiple sclerosisnaUK21m6310:006.521614Multiple sclerosis (PMS, likely PPMS)Aspiration pneumonia and sepsis; advanced MS30NBB22f6108:046.411155Multiple sclerosis (SPMS)Urosepsis and hydronepfronis22NBB23m7005:106.821181Multiple sclerosis (SPMS)Dehydration, decompensation cordis, MS; palliative sedation21NBB*PMD* Post-mortem delay, *f* Female, *m* Male, *na* Not available, *s.i.c.c* Senile involutive cortical changes, *NBB* Netherlands Brain Bank, *UK* Multiple Sclerosis Society Tissue Bank

Immunohistochemistry {#Sec4}
--------------------

CP tissue was sliced in 5 μm sections, deparaffinized and washed with MilliQ (Millipore). Heat-mediated antigen retrieval was performed in the corresponding buffer (Table [2](#Tab2){ref-type="table"}). Sections were cooled on ice for 30 min and washed with phosphate buffered saline (PBS). Subsequently, sections were blocked with PBS containing 10% normal serum (from the host of the secondary antibody) or bovine serum albumin (BSA, Fraction V, Roche Diagnostics; when using antibodies from multiple hosts) and 0.05% Tween20 (Sigma-Aldrich) for 20 min. Primary antibodies (Table [2](#Tab2){ref-type="table"}) were diluted in PBS containing 1% normal serum or BSA and 0.05% Tween20, and incubated in the dark overnight at 4 °C or for 1 h at room temperature. Then, sections were washed with PBS. Alexa fluorophore-conjugated secondary antibodies (Thermo Fisher Scientific) were diluted in PBS containing 0.05% Tween20 and incubated for 1h at room temperature in the dark*.* After washing with PBS, sections were incubated with Hoechst (33,258, Thermo Fisher Scientific), for nuclear visualization, diluted in PBS to a final concentration of 10 μg/mL for 1 minute in the dark. Sections were washed with PBS, mounted with Mowiol medium and a coverslip (Menzel-Glaser, thickness \#1) and stored in the dark at 4 °C until image acquisition. Table 2Antibody detailsTargetMarkerHostClonality (clone)End concentrationCompany (catalog number)Antigen retrievalAPCsMHCIIMouseMonoclonal (LN3)6.8 μg/mLHybridomaCitrateB cellsCD19RatMonoclonal (6OMP31)0.5 μg/mLThermo Fisher Scientific (14--0194-82)CitrateBasement membraneCollagen IVRabbitPolyclonal3.3 μg/mLAbcam (ab6586)Tris or citrateCD4+ T cellsCD4RabbitMonoclonal (EPR6855)1.1 μg/mLAbcam (ab133616)TrisCD8+ T cellsCD8MouseMonoclonal (C8/144B)0.157 μg/mLDako (M7103)TrisEndothelial cellsBiotinylated UEA I Europaeus Agglutinin I (UEA I)2.0 μg/mLVector laboratories (B-1065)TrisGranulocytesCD66b (A647 label)MouseMonoclonal (G10F5)4.5 μg/mLNovus Biologicals (NB100-77808AF647)CitrateMyeloid cellsIba1GoatPolyclonal1.0 μg/mLAbcam (ab5076)CitratePlasma cellsCD138MouseMonoclonal (MI15)Not available (1:50)Thermo Fisher Scientific (MA5--12400)CitrateT cellsCD3MouseMonoclonal (F7.2.38)2.8 μg/mLDako (M7254)TrisT cellsCD3RabbitPolyclonal3.0 μg/mLDako (A0452)Tris*APCs* Antigen-presenting cells, Tris: 10 mM Tris / 1 mM EDTA, pH 9; Citrate: 10 mM sodium citrate buffer, pH 6

Image acquisition and immunostaining scoring {#Sec5}
--------------------------------------------

After immunohistochemistry, sections were visualized using a Nikon A1R+ HD confocal galvano scanning laser microscope with 20x magnification and the NIS-Elements software (Nikon). Three image fields per sample displaying characteristic CP morphology were picked based on the basement membrane (collagen IV), while blinded to the other fluorophore channels before final imaging. Because of the abundance of cells in the Iba1/MHCII panel, only one image field was captured. To improve quantification of the Iba1/MHCII and CD66b stainings, a z-stack was created consisting of nine one-micrometre steps. ImageJ was used to process the images, outline the different CP compartments, manually count the cells and quantify the tissue area \[[@CR1]\]. This method allows for a quantitative scoring of the immune cells in each of the CP compartments. Imaging and scoring were performed blinded.

For visualization of the interaction between MHCII+ cells with T cells we used a Leica TCS SP8 microscope (Leica Microsystems) and the Leica Application Suite Advanced Fluorescence software (Leica Microsystems). Fifteen non-circulating CD3+ T cells were selected per sample and assessed for interaction with MHCII+ cells.

Data analysis {#Sec6}
-------------

Data were analyzed using R version 3.4.2 \[[@CR29], [@CR30]\]. For the immune cell quantification, the number of identified immune cells was corrected for analyzed tissue area to calculate cell density. The obtained data were assessed for normality using a Shapiro-Wilk test. In the case of normality, differences between groups were evaluated with a Welch Two Sample t-test. Alternatively, a Wilcoxon rank sum test was applied. Data are reported as the median. Correlations were calculated using the Pearson correlation coefficient. PCA was performed in R using the density of CP (stromal and epithelium-associated) MHCII+ macrophages, MHCII- macrophages, dendritic cells (DCs), total T cells, CD4+ T cells, CD8+ T cells, B cells or plasma cells, granulocytes and the percentage of T cells interacting with MHCII+ cells.

Results {#Sec7}
=======

Macrophages and dendritic cells densely populate the CP of both progressive MS patients and controls {#Sec8}
----------------------------------------------------------------------------------------------------

In order to characterize the density and location of the immune cell populations within the CP, we performed immunohistochemical analysis of well characterized post-mortem CP of progressive MS cases and non-neuroinflammatory control cases (patient details in Table [1](#Tab1){ref-type="table"}). The visualized CP area was divided into three compartments using the epithelial and endothelial basement membranes (stained by collagen IV) to guide this division. The cellular location was defined as either in the circulation ("vessel", excluded from the analyses; Additional file [2](#MOESM2){ref-type="media"}: Figure S1), in the stromal compartment ("stroma") or associated to the epithelium ("epithelium") (Fig. [1](#Fig1){ref-type="fig"}a). Fig. 1Density of macrophages and DCs is similar in the CP of progressive MS patients and controls**. a** Example of the compartmentalization of the CP tissue. Using the basement membrane as guidance (collagen IV, in white), we discern the stromal and epithelium-associated cells (which together are the CP cells), and exclude the circulating cells located in the vessels. **b** Maximum projection of an image of a CP immunolabeled with Iba1, MHCII and collagen IV. Right panel shows a higher magnification of the image. White arrowheads point to one MHCII+ and one MHCII- macrophage (Iba1+) in the CP stroma; white arrow points to a dendritic cell (DC; Iba1- MHCII+) associated to the epithelium. **c** Density of CP macrophages (MHCII+ and MHCII-) in control and progressive MS (Wilcoxon rank sum test with continuity correction). **d** Density of CP macrophages in the different CP compartments (Welch Two Sample t-test and Wilcoxon rank sum test with continuity correction). **e** Density of CP DCs in control and progressive MS (Wilcoxon rank sum test). **f** Density of CP DCs in the different CP compartments (Wilcoxon rank sum test and Welch Two Sample t-test). Col IV: collagen IV; PMS: progressive MS. Scale bars are 100 μm

To assess the presence of macrophages and dendritic cells (DCs), we immunolabelled CP tissue with Iba1 and MHCII (HLA-DR). The CP of both control and progressive MS cases was densely populated by macrophages (Iba1+ cells) and DCs (defined as Iba1- MHCII+ cells) (Fig. [1](#Fig1){ref-type="fig"}b-f). Most of the macrophages were positive for MHCII (Fig. [1](#Fig1){ref-type="fig"}c), suggesting their involvement in local antigen presentation; however, a small subset of stromal macrophages was negative for MHCII (Fig. [1](#Fig1){ref-type="fig"}b-d). Both macrophages and DCs were mainly located in the stromal compartment (Fig. [1](#Fig1){ref-type="fig"}d and f). No differences in macrophage or DC densities were observed between progressive MS and control cases in any of the CP compartments (Fig. [1](#Fig1){ref-type="fig"}c-f). In summary, macrophages and DCs densely populate the CP of both controls and progressive MS patients.

CD8+ T cells are more abundant in progressive MS CP compared to control CP {#Sec9}
--------------------------------------------------------------------------

As T cells have previously been shown to enter the CNS through the CP in EAE \[[@CR23]\], we next assessed the density and distribution of T lymphocytes in the CP of control and progressive MS patients. CD3+ T cells were present in the CP of both control and progressive MS patients (Fig. [2](#Fig2){ref-type="fig"}). Importantly, the density of CD3+ T cells was significantly higher in the CP of progressive MS (4.19e-5 cells/μm^2^) compared to control CP (1.15e-5 cells/μm^2^; Fig. [2](#Fig2){ref-type="fig"}b). This difference was mainly due to a higher T cell density in the stromal compartment, where the vast majority of T cells were located (Fig. [2](#Fig2){ref-type="fig"}c). Fig. 2T cell density is higher in the CP stroma of progressive MS patients than in the control CP, and they interact with APCs. **a** Representative images of the control and progressive MS CP immunolabeled with CD3 and collagen IV. White arrowheads point to stromal CD3+ T cells. Scale bars are 100 μm. **b** Density of CP T cells in the CP of control and progressive MS cases (Welch Two Sample t-test). **c** Density of CP T cells in the different CP compartments (Wilcoxon rank sum test). **d** Representative image of a T cell (CD3+, green) in close contact with an APC (MHCII+, red); vessels are visualized with UEA I (white). Maximum projection is accompanied by the orthogonal views. Scale bar is 10 μm. **e** Absolute density of T cells in close contact with MHCII+ APCs in the CP of control and progressive MS patients, calculated by applying the percentage of T cells that were interacting with APCs to the total density of T cells in their respective samples (Welch Two Sample t-test). **f** Percentage of T cells interacting with APCs in the CP of control and progressive MS patients, defined as the CP T cells located directly adjacent to MHCII+ cells (Welch Two Sample t-test). **g** Lack of correlation between interacting T cells and the total CP T cells in each sample (Pearson's correlation). PMS: progressive MS

Previous research showed that T lymphocytes can infiltrate the mouse CP for re-activation and proliferation \[[@CR28]\]. To address this phenomenon in the human CP, we studied the spatial association between CD3+ T cells and MHCII+ APCs in the CP stroma. The presence of T cells adjacent to APCs was commonly observed in both control and progressive MS (Fig. [2](#Fig2){ref-type="fig"}d, Additional file [2](#MOESM2){ref-type="media"}: Figure S2a-b and Additional file [3](#MOESM3){ref-type="media"}: Movie 1). While the calculated absolute number of interacting T cells was higher in progressive MS than in control (Fig. [2](#Fig2){ref-type="fig"}e), this was due to the higher density of T cells and there were no differences in the percentage of interacting T cells between the groups (Fig. [2](#Fig2){ref-type="fig"}f). Indeed, there was no correlation between the percentage of interacting T cells and the corresponding density of total CP T cells in the MS group (Fig. [2](#Fig2){ref-type="fig"}g).

To further define the phenotype of these T cells, we analyzed CD4+ helper and CD8+ cytotoxic T cell subsets, with the aid of the endothelial marker UEA I to exclude circulating cells located in the vessels. Both CD4+ and CD8+ T cells were present in the CP of all cases, but only CD8+ T cell density was significantly higher in progressive MS patients 2.83e-5 cells/μm^2^) relative to controls (1.53e-5 cells/μm^2^; Fig. [3](#Fig3){ref-type="fig"}a and b). Both CD4+ and CD8+ T cells were found in close contact with APCs (Fig. [3](#Fig3){ref-type="fig"}c, Additional file [2](#MOESM2){ref-type="media"}: Figure S2c). Together, our data indicate that T cells are present in the CP, where they interact with APCs in both controls and progressive MS patients, and that there is a higher density of CD8+ T cells in progressive MS patients relative to controls. Fig. 3CD8+ T cell density is significantly higher in the CP stroma of progressive MS patients relative to that of controls. **a** Representative images of the progressive MS and control CP immunolabeled with CD4 (green), CD8 (red) and UEA I (white). White arrows point to CD4+ T cells, while white arrowheads point to CD8+ T cells. **b** Density of CP CD4+ and CD8+ T cells in the CP of control and progressive MS patients (Wilcoxon rank sum test). Scale bars are 100 μm. **c** Representative image of a CD4+ T cell (green) and a CD8+ T cell (red) in close contact with an APC (MHCII+, white). Maximum projection is accompanied by the orthogonal views. Scale bar is 10 μm. PMS: progressive MS

B cells and plasma cells are virtually absent from the CP {#Sec10}
---------------------------------------------------------

B cells are implicated in the pathogenesis of progressive MS, as demonstrated by the efficacy of CD20-targeted therapies \[[@CR7], [@CR8], [@CR13], [@CR25]\]. In the meninges, B cells and plasma cells are present in the follicle-like structures found in some progressive MS patients \[[@CR22], [@CR26]\], and there are more B cells in the CSF of progressive MS patients relative to controls \[[@CR10]\]. Thus, we set out to investigate whether B cells and plasma cells are present in the CP of progressive MS patients and controls. In most MS patients and all controls, we did not observe any B cells (marked by CD19) and/or plasma cells (marked by CD138). In one progressive MS patient, a double positive cell for CD19 and CD138 was identified in the stroma (Fig. [4](#Fig4){ref-type="fig"}). Only one CD19+ CD138- B cell was detected in our patient cohort (Fig. [4](#Fig4){ref-type="fig"}a-b). In sum, B cells and plasma cells are virtually absent from the CP of both progressive MS patients and controls. Fig. 4B and plasma cells are virtually absent from the CP. **a** Examples of CD19+ and CD138+ cells in the CP of progressive MS patients; basement membrane was immunolabeled with collagen IV. White arrowhead in the top panel points to a CD19+ CD138+ cell; in the lower panel, a CD19+ B cell is seen. **b** Density of CP CD19+ cells in the different CP compartments (Wilcoxon rank sum test with continuity correction). **c** Density of CP CD138+ cells in the different CP compartments (Wilcoxon rank sum test with continuity correction). PMS: progressive MS. Scale bars are 50 μm

Granulocytes are more abundant in the CP of progressive MS patients compared to control CP {#Sec11}
------------------------------------------------------------------------------------------

The role of granulocytes has been underappreciated in MS pathology \[[@CR33]\]. We studied the presence of granulocytes in the CP using the marker CD66b. As expected due to their abundance in blood, most of the granulocytes were detected in the vessels (Additional file [2](#MOESM2){ref-type="media"}: Figure S1f). In progressive MS patients, the density of non-circulating granulocytes was significantly higher than in controls (5.26e-6 cells/μm^2^ vs 0 cells/μm^2^; Fig. [5](#Fig5){ref-type="fig"}b). This difference was mainly due to the stromal compartment (Fig. [5](#Fig5){ref-type="fig"}c), although in the progressive MS CP epithelium there was also a trend to a higher density of granulocytes compared to the control. Preliminary stainings show that most of the granulocytes were neutrophils, as shown by their expression of elastase (Additional file [2](#MOESM2){ref-type="media"}: Figure S3). These findings indicate that granulocyte infiltration is apparent in the CP of progressive MS patients. Fig. 5Granulocyte density is higher in the CP of progressive MS patients relative to the control CP. **a** Maximum projection image of a progressive MS and a control CP immunolabeled with CD66b (red) and collagen IV (white). White arrowhead points to a granulocyte associated with the epithelium and white arrow points to a stromal granulocyte in the progressive MS case. **b** Density of CP granulocytes in the CP of control and progressive MS cases (Wilcoxon rank sum test with continuity correction). **c** Density of CP granulocytes in the different CP compartments (Wilcoxon rank sum test with continuity correction). PMS: progressive MS. Scale bars are 100 μm

Discussion {#Sec12}
==========

By using human post-mortem CP tissue in combination with immunohistochemistry and confocal microscopy, we here provide a comprehensive overview of immune cell populations present in the CP of non-neuroinflammatory controls and progressive MS cases, both in terms of abundance and of their location within the different CP compartments (summarized in Fig. [6](#Fig6){ref-type="fig"} and Additional file [1](#MOESM1){ref-type="media"}: Table S1). For the first time, we show that both CD8+ T cells and granulocytes are more abundant in the CP stroma of progressive MS cases compared to controls. Around one third of the T cells appeared to be in close contact with APCs in the CP regardless of disease status, suggesting that local antigen presentation is a constitutive event in the CP. Furthermore, we show that macrophages, particularly those expressing MHCII, and DCs are abundant in CP of both MS patients and controls, with the majority located in the stroma but also associated with the epithelium. In contrast, B and plasma cells were rarely observed in both the MS and control CP. Fig. 6Graphical summary of the immune cell populations in the CP of progressive MS patients and controls. X axis shows the density of each immune cell population in control and progressive MS CP. The area of each bar represents the mean density of the corresponding cell type and disease status. The bar length represents the relative contribution of each disease status to the total cells of a particular subset. Significant alterations in the density of cell populations between progressive MS and control cases are represented with an asterisk. Fold change could not be calculated for B or plasma cells due to the 0 values in the control cases. PMS: progressive MS

The CP is a strategically located, highly vascularized structure within the brain ventricles with CNS homeostatic properties. The CP acts as a bidirectional immunosurveillance system by means of the BCSFB \[[@CR28]\]. To date, relatively little is known about the immune cell populations in the human CP under normal and inflammatory conditions. We here provide a detailed characterization of the main immune cell populations in the CP of controls and progressive MS patients, which can be a resource for researchers in the field of brain barriers and MS, while helping to better understand the inflammatory processes in the progressive phases of MS.

T cells play a central role in the pathogenesis of MS \[[@CR15], [@CR19]\]. Here, we observed that the CP presents a higher density of T cells in MS patients relative to controls, in line with a previous study of Vercellino and co-workers \[[@CR32]\]. We further demonstrated that T lymphocytes are also present in control individuals, as reported before \[[@CR16]\]. In contrast, another study found no T cells in control CP \[[@CR32]\], which may be explained by a small number of control cases used in that study. T cells are predominantly localized in the stromal compartment of the CP. Stromal T lymphocytes may be infiltrated from the periphery into the CNS \[[@CR23]\], migrated from the CSF into the CP for re-activation \[[@CR28]\] or remain in the CP as tissue resident T cells. The relative scarcity of epithelium associated T cells, together with the lack of changes in T cell numbers in the CSF of progressive MS patients \[[@CR10]\], supports the view that T cells in the CP of progressive MS are restricted to the stromal compartment and do not cross the BCSFB at the CP. However, we cannot exclude the possibility that subtle differences in epithelial T cell density are missed due to the brevity of the migration process and the relative small size of the epithelial compartment, which result in a low chance of detecting them. CD8+ T cells are the predominant T cell subtype in MS lesions \[[@CR3]\] and we observed accumulation of CD8+ T cells in the progressive MS CP. While CD8+ T cells within the brain have detrimental effects on CNS cells, those restricted to the CNS borders may exert immunosuppressive effects \[[@CR14], [@CR15], [@CR31]\], or simply reside as tissue memory T cells as a result of previous inflammatory processes.

The role of granulocytes in MS pathology has been underappreciated as they are rarely reported in MS lesions \[[@CR2], [@CR33]\]. In RRMS, the number of neutrophils in the CSF decreases with disease duration \[[@CR18]\]; in contrast, PPMS subjects have more granulocytes than RRMS patients in the CSF \[[@CR10]\]. Interestingly, our unpublished findings showed that the neutrophil chemoattractant gene *CXCL2* is upregulated in the CP of progressive MS patients. Here, we observed more granulocytes in the CP of progressive MS patients compared to the CP from controls. Because granulocytes have a particularly short lifespan, our results point to a continuous infiltration from the peripheral circulation at this chronic stage of the disease. Although granulocytes are typically regarded as innate immune cells detrimental for tissue repair, the release of reactive oxygen species and degranulation can also have a regulatory effect in the adaptive immune system. As such, neutrophils exert an immunosuppressive effect on T cell responses to myelin \[[@CR34]\]. Whether they play a similar role in the progressive MS CP and thereby restrict T cell infiltration at the CP needs to be further elucidated.

Macrophages and DCs are the predominant immune cell type in the CP stroma. Their antigen-presenting capacity is illustrated by the expression of MHCII on their surface. In addition to their stromal location, we observed that macrophages and DCs were associated with the CP epithelium, either protruding among epithelial cells or associated with the apical surface of the epithelium (known as Kolmer cells or epiplexus macrophages), which confirms and extends earlier observations \[[@CR11], [@CR27], [@CR32]\]. These epithelium-associated immune cells at the BCSFB are likely a bridge between the peripheral and CNS immune systems \[[@CR11], [@CR12]\]. Thus, the CP may have constitutive functions in CNS homeostasis through this niche of macrophages and DCs, such as local presentation of CNS antigens.

Our study revealed the virtual absence of B cells and plasma cells in the CP. Importantly, our results are in line with previous research, which described very rare CD138+ plasma cells and an absence of CD20+ B cells \[[@CR32]\]. Thus, the CP does not appear to be an initial CNS-entry site for B cells during the progressive phase of MS. Instead, B cells present in the meninges of progressive MS patients \[[@CR22], [@CR26]\] may represent the primary source of infiltrating B cells into the CSF.

This study is constrained by the availability of human CP tissue. Thus, the variability in the immune populations between donors (Additional file [2](#MOESM2){ref-type="media"}: Figure S4) may have hindered the detection of subtle differences. It would be interesting to explore the CP immune cell composition of RRMS patients, however we could not obtain high quality CP samples from RRMS patients. Despite the heterogeneity in immune cell densities among the patients, we did not find differences between PPMS and SPMS patients (Additional file [2](#MOESM2){ref-type="media"}: Figure S5). Although PPMS and SPMS present different disease courses, in both progressive forms of MS neurodegeneration predominates over acute inflammation. Accordingly, a moderately inflamed status is seen in the CP of both PPMS and SPMS patients. Although we tried to use consensus cellular markers, no single marker can identify human DCs. By defining DCs as MHCII+ Iba1-, we could not exclude other APCs, such as B cells or activated T cells. However, considering the scarcity of B cells and the lack or subtle expression of MHCII by T cells in the CP, we expect this error to be negligible. Lastly, the use of fixed post-mortem material provides only a snapshot of a dynamic process that cannot fully reflect the progression of the disease.

In summary, this study provides a detailed characterization of the density and location of immune cell populations present in the human CP, as well as alterations thereof in progressive MS. The presence of immune cells in non-neuroinflammatory controls highlights the role of the CP in immune surveillance and homeostasis. Further, we provide insight into the involvement of the inflammatory component of the CP in progressive MS. Particularly, the abundance of T cells and granulocytes at the CP in progressive MS patients implicate both the adaptive and innate immune systems in the chronic progressive phases of MS. However, their restriction to the stromal compartment argues against the CP as a major entry route of immune cells into the CNS during progressive MS. Future research is warranted to unravel the functional consequences of the immune changes in the CP, and how these may in turn affect the CNS of MS patients.

Supplementary information
=========================

 {#Sec13}

**Additional file 1: Table S1**. Density of CP (stromal and epithelium-associated) immune cell populations in control and progressive MS patients. **Additional file 2: Figure S1.** Immune cells located in the vessel compartment of the CP of progressive MS patients and controls. **a)** Iba1+ cells and their MHCII expression. **b)** Iba1- MHCII+ cells. **c)** CD3+ T cells. **d)** CD19+ B cells. **e)** CD138+ plasma cells. **f)** CD66b + granulocytes (Wilcoxon rank sum test with continuity correction). C: control; PMS: progressive MS. **Figure S2.** T cells in close contact with APCs in the CP stroma. **a)** Representative images of the CP immunolabeled with CD3 (green) and MHCII (red); vessels are visualized with UEA I (white). White arrowheads point to a CD3+ T cell in close contact with an MHCII+ APC (left panel), and to a non-interacting T cell (right panel). **b)** On the top panel, three T cells can be seen: one is not interacting with any MHCII+ cell (white arrow), while the other two are in close contact with MHCII+ cells (white arrowheads). The middle and lower panels show higher magnification of T lymphocytes interacting with APCs. **c)** Percentage of CD4+ T cells and CD8+ T cells interacting with APCs in the CP of control and progressive MS patients, defined as the T cells located directly adjacent to MHCII+ cells (Wilcoxon rank sum test with continuity correction). Scale bar is 10 μm. **Figure S3.** Most granulocytes in the CP are neutrophils. Representative images of one CP section immunolabeled with CD66b (red) and elastase (green). Maximum projection image. White arrowheads point to CD66b + elastase+ neutrophils. Scale bars are 50 μm. **Figure S4.** PCA plot of the samples used in this study, showing standardized principal components 1 and 2. Axes show the percentage of variance explained by each principal component. Variables included in the analysis: density of CP MHCII+ macrophages, MHCII- macrophages, DCs, total T cells, CD4+ and CD8+ T cells, percentage of T cells interacting with MHCII+ cells, B or plasma cells and granulocytes. PC: principal component; PMS: progressive MS. **Figure S5.** PPMS and SPMS patients present similar non-circulating (stromal and epithelium-associated) immune cell subsets in the CP. **a)** Density of non-circulating CD3+ T cells in PPMS and SPMS patients (Welch Two Sample t-test). **b)** Ratio of non-circulating CD4+ vs CD8+ T cells in PPMS and SPMS patients (Welch Two Sample t-test). **c)** Density of non-circulating MHCII+ macrophages in PPMS and SPMS patients (Welch Two Sample t-test). **d)** Density of non-circulating MHCII- macrophages in PPMS and SPMS patients (Welch Two Sample t-test). **d)** Density of non-circulating Iba1-MHCII+ DCs in PPMS and SPMS patients (Wilcoxon rank sum test). **e)** Density of non-circulating granulocytes in PPMS and SPMS patients (Wilcoxon rank sum test). PPMS: Primary Progressive MS; SPMS: Secondary Progressive MS **Additional file 3: Movie 1.** Example of a T cell (CD3+, green) adjacent to an APC (MHCII+, red) in the CP. Nuclei are in blue and vessels are marked with UEA I in white.
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